| |
| | Use of guanylate cyclase inhibitors in the treatment of shock - Patent 5298506 |
 | | The invention relates to the administration of guanylate cyclase inhibitors, such as methylene blue, for the treatment of septic shock, cardiogenic shock, hypovolemic shock, obstructive shock, neuropathic shock and hypotension caused by excessive doses of nitrovasodilators. |
 | | The method of claim 1 wherein said guanylate cyclase inhibitor is selected from the group consisting of methylene blue, 6-anilino-5, 8-quinolinedione, N-methylhydroxylamine, hydroxylamine, ethacrynic acid and retinol. |
 | | Finally, methylene blue inactivates guanylate cyclase, the enzyme responsible for raising cyclic GMP levels, which is critical, as the cGMP second messenger is central to the hypotensive effect of NO. |
| www.freepatentsonline.com /5298506.html (2423 words) |
|